It does seem strange they'd mention mid 2024, particularly when first patient dosed announcement was Jan 17 this year. Assuming at least a 3-4 month follow-up then they're predicting 26 enrolments in the space of a few months? Odd. Would have to be super quick enrolment. They did mention that historically Korea enrolment in pancreatic ca trials has been strong, but this seems a big stretch.
The Korea link is intriguing.
ATX Price at posting:
7.6¢ Sentiment: Buy Disclosure: Held
